Mr. Bill Radvak reports

NERVGEN PHARMA ANNOUNCES RESULTS OF ANNUAL GENERAL MEETING OF SHAREHOLDERS

Nervgen Pharma Corp. has released the results of its annual general meeting of shareholders held on May 17, 2023.

"We appreciate the support demonstrated by our shareholders at this AGM," stated Bill Radvak, Nervgen's chairman. "With our phase 1 clinical trial successfully concluded, we are looking forward to the advancement of our proprietary lead drug candidate, NVG-291, into a phase 1b/2a clinical trial in individuals with spinal cord injury in [third quarter] of this year."

The company reports that at the AGM, the shareholders re-elected Brian Bayley, Harold Punnett, Bill Radvak, Randall Kaye, Krista McKerracher, Glenn Ives, Craig Thompson, Adam Rogers and Michael Kelly to serve in office until the next annual meeting or until their successors are duly elected or appointed. The shareholders also voted in favour of the appointment of KPMG LLP, chartered accountants, as auditor of the company until the next annual meeting of the company's shareholders or until its successors are duly appointed. In addition, the shareholders approved by disinterested shareholder vote, certain amendments to the company's existing stock option plan.

About Nervgen Pharma Corp.

Nervgen (TSX Venture Exchange: NGEN) (OTCQX: NGENF) is a clinical-stage biotech company dedicated to developing innovative treatments that enable the nervous system to repair itself following damage, whether due to injury or disease. Nervgen's lead drug candidate, NVG-291, is currently planned for a phase 1b/2a clinical trial. The company's initial target indications include spinal cord injury, Alzheimer's disease and multiple sclerosis.

We seek Safe Harbor.